Center for Stem Cell Therapeutics and Imaging (CSTI), Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Center for Stem Cell Therapeutics and Imaging (CSTI), Harvard Medical School, Boston, MA 02115, USA; Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, MI 48109-1085, USA.
Trends Cancer. 2021 Sep;7(9):809-822. doi: 10.1016/j.trecan.2021.02.003. Epub 2021 Mar 12.
Patients with extracranial tumors, like lung, breast, and skin cancers, often develop brain metastases (BM) during the course of their diseases and BM commonly represent the terminal stage of cancer progression. Recent insights in the immune biology of BM and the increasing focus of immunotherapy as a therapeutic option for cancer has prompted testing of promising biological immunotherapies, including immune cell-targeting, virotherapy, vaccines, and different cell-based therapies. Here, we review the pathobiology of BM progression and evaluate the potential of next-generation immunotherapies for BM tumors. We also provide future perspectives on the development and implementation of such therapies for brain metastatic cancer patients.
患有颅外肿瘤的患者，如肺癌、乳腺癌和皮肤癌，在疾病过程中经常会发展出脑转移（BM），而 BM 通常代表癌症进展的终末期。近年来，对 BM 的免疫生物学的深入了解以及将免疫疗法作为癌症治疗选择的日益关注，促使人们对有前途的生物免疫疗法进行了测试，包括免疫细胞靶向治疗、病毒疗法、疫苗和不同的细胞疗法。在这里，我们回顾了 BM 进展的病理生物学，并评估了下一代免疫疗法在 BM 肿瘤中的潜力。我们还对脑转移癌患者开发和实施此类疗法的未来前景进行了展望。
